Related Experiment Videos
[Ectopic calcification in patients with aplastic bone disease undergoing dialysis]
1Department of Internal Medicine, Kasugai Municipal Hospital.
Clinical Calcium
|March 19, 2005
Summary
Aplastic bone disease, common in dialysis patients, stems from low parathyroid hormone. High calcium and phosphorus products in these patients increase risks, highlighting the need for careful monitoring.
Area of Science:
- Nephrology
- Endocrinology
- Bone Metabolism
Context:
- Aplastic bone disease (adynamic bone disease) is the most frequent renal osteodystrophy in dialysis patients.
- Low serum parathyroid hormone levels are the primary cause.
- Characterized by reduced osteoblast and osteoclast numbers, leading to low bone turnover.
Purpose:
- To highlight the disturbed calcium and phosphorus buffering in aplastic bone disease.
- To explain the mechanism leading to high serum calcium and phosphorus product.
- To emphasize the association between high calcium-xphosphorus product and ectopic calcification.
Summary:
- Low bone turnover in aplastic bone disease impairs calcium and phosphorus regulation.
- Hypercalcemia and hyperphosphatemia can result from calcium carbonate and high protein diets.
- This leads to elevated serum calcium and phosphorus product, increasing ectopic calcification risk.
Impact:
- Ectopic calcification, particularly in arteries, can cause ischemic changes in visceral organs.
- High serum calcium and phosphorus product is a significant risk factor for patient survival.
- Close attention to calcium and phosphorus product levels is crucial for managing aplastic bone disease patients.